AXITINIB STADA 1mg tablets medication leaflet

L01EK01 • axitinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

Axitinib is a selective tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma. It works by blocking vascular endothelial growth factor receptors (VEGFR), reducing angiogenesis and inhibiting tumor growth.

Axitinib is administered orally, usually twice daily, with the dose adjustable based on patient tolerability and response. It is indicated for patients with advanced renal cell carcinoma who have progressed after prior treatments such as sunitinib or cytokines.

Common side effects include hypertension, diarrhea, fatigue, nausea, and loss of appetite. In rare cases, severe adverse reactions such as thromboembolic events, hemorrhages, or gastrointestinal perforations may occur. Regular monitoring of blood pressure and other clinical parameters is essential during treatment.

Axitinib represents an effective therapeutic option for patients with advanced renal cell carcinoma, contributing to prolonged survival and disease control.